dalteparin has been researched along with Meningeal Neoplasms in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with brain tumors including intracranial meningiomas are at increased risk for developing deep vein thrombosis (DVTs) and suffering thromboembolic events (VTEs)." | 1.35 | Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. ( Berger, MS; Cage, TA; Chakalian, L; Frankfurt, A; Lamborn, KR; McDermott, MW; Ware, ML, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cage, TA | 1 |
| Lamborn, KR | 1 |
| Ware, ML | 1 |
| Frankfurt, A | 1 |
| Chakalian, L | 1 |
| Berger, MS | 1 |
| McDermott, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for dalteparin and Meningeal Neoplasms
| Article | Year |
|---|---|
Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Chemotherapy, Adjuvant; Enoxaparin; Female; Humans; | 2009 |